Our take on the latest news and views on data.

Relevant company news, articles, podcasts, and blog posts.

Recent Posts

Industry Trends

Clinical Trial Trends

Disease Area Trends

Recent Tweets

$ACOGF FDA accepts Alpha Cognition's NDA for ALPHA-1062, treating Mild-to-Moderate Alzheimer's Disease.

More Info: https://pryzm.ozmosi.com/product/26208 $XBI $IBB $XPH $PPH

FDA approves Avzivi® (bevacizumab-tnjn), a Biosimilar by Bio-Thera Solutions, referencing Avastin®.

More Info: https://pryzm.ozmosi.com/product/19006 $XBI $IBB $XPH $PPH

📅Future Pharm/Biotech Catalysts Dates announced this week 📈

December 13, 2023
$BCAB BA-3071

December 11, 2023
$NRIX NX-2127|NX-5948
$SNDX Axatilimab|Revumenib

December 12, 2023

December 10, 2023
$EGRX Amisulpride

DAN-222, an innovative drug conjugate developed by Dantari, displays potential antitumor effects in HER2-negative breast cancer patients with metastasis.

More Info: https://pryzm.ozmosi.com/product/25258 $XBI $IBB $XPH $PPH

Load More

Get Started with OZMOSI

We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.

600 Warren Ave,
Spring Lake, NJ 07762